Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2

Elias Tayar; Ryan Isber; Nidal Isber

doi:10.1016/j.heliyon.2023.e17149

Long COVID treated successfully with antivirals in a rituximab-treated follicular lymphoma patient with persistent negative-antibodies to SARS-CoV2

Heliyon. 2023 Jun;9(6):e17149. doi: 10.1016/j.heliyon.2023.e17149. Epub 2023 Jun 21.

Authors

Elias Tayar¹, Ryan Isber², Nidal Isber³

Affiliations

¹ Hamad Medical Corporation, Doha, Qatar.
² Binghamton University, New York, USA.
³ Richmond University Medical Center, New York, USA.

Abstract

Long COVID is a well-known complication to COVID-19 that affect millions of people worldwide and causes wide range of symptoms. We present a rare case of a previously diagnosed follicular lymphoma patient, who had a long COVID with persistent negative SARS-CoV-2 antibodies and required an aggressive antiviral treatment.

Keywords: Antivirals; COVID-19; Follicular lymphoma; Long COVID.

Publication types

Case Reports